At-Home Starting Dose for Lecanemab in Early Alzheimer Disease

The FDA approved a new starting dosage regimen for subcutaneous lecanemab-irmb (Leqembi Iqlik, Eisai Inc.), an amyloid beta-directed antibody for adults with Alzheimer disease. The action allows patients to begin treatment at home through self-administration or administration by a caregiver instead of receiving initial intravenous (IV) infusions in a clinic.

Supporting trials enrolled patients with confirmed amyloid pathology who had mild cognitive impairment or mild dementia due to Alzheimer disease. Previously, lecanemab could be started only intravenously, with the option to transition to IV or subcutaneous maintenance dosing after 18 months.

Evidence supporting lecanemab included two large randomized, placebo-controlled trials, Study 1 (NCT01767311) and Study 2 (NCT03887455). Neither participants nor investigators knew the assigned treatment. Both studies evaluated IV lecanemab at 10mg/kg every 2 weeks for 18 months, followed by an optional longer-term extension. The FDA based the new subcutaneous regimen on the IV trial findings and evidence comparing the formulations. According to the agency, subcutaneous dosing demonstrated equivalence to IV treatment in the body and produced comparable amyloid plaque reductions; it was not evaluated in a separate large trial designed to measure clinical outcomes.

The prescribing information includes a boxed warning for amyloid-related imaging abnormalities (ARIA), which most commonly appear as temporary brain swelling on imaging and may be accompanied by small areas of bleeding. ARIA can occasionally cause serious or life-threatening events. Patients homozygous for the ApoE ε4 allele have a higher incidence of ARIA, including symptomatic, serious, and severe events. The labeling states that testing for ApoE ε4 status should be performed before treatment.

Leqembi Iqlik may also cause injection-related reactions, including localized redness, swelling, rash, pain, or bruising. The prescribing information recommends caution in patients taking anticoagulants or with other risk factors for intracerebral hemorrhage. The FDA granted the application Priority Review.

Sources: FDA. FDA approves first at-home starting dose for Alzheimer’s disease treatment. News release. FDA; July 13, 2026. Accessed July 14, 2026.